Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 2/20 | 0.49 |
| ▸ | JAK1 | P23458 | 2/20 | 0.49 |
| ▸ | HPGDS | O60760 | 1/20 | 0.48 |
| ▸ | JAK3 | P52333 | 6/20 | 0.46 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.45 |
| ▸ | LCK | P06239 | 1/20 | 0.45 |
| ▸ | TTBK1 | Q5TCY1 | 2/20 | 0.43 |
| ▸ | TTBK2 | Q6IQ55 | 2/20 | 0.43 |
| ▸ | AKT2 | P31751 | 1/20 | 0.41 |
| ▸ | GSK3B | P49841 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12561873 | 0.87 | JAK2 (0.61) | JAK2JAK1HPGDSIRAK4LCK | |
| SCHEMBL3535971 | 0.86 | JAK2 (0.50) | JAK2JAK1HPGDSJAK3IRAK4 | |
| SCHEMBL3539656 | 0.83 | JAK2 (0.55) | JAK2JAK1HPGDSJAK3IRAK4 | |
| SCHEMBL3537761 | 0.83 | JAK2 (0.49) | JAK2JAK1HPGDSJAK3IRAK4 | |
| SCHEMBL3532731 | 0.81 | JAK1 (0.54) | JAK2JAK1HPGDSJAK3IRAK4 | |
| SCHEMBL3532554 | 0.81 | JAK3 (0.53) | JAK2JAK1HPGDSJAK3IRAK4 | |
| SCHEMBL3534101 | 0.81 | JAK1 (0.66) | JAK2JAK1HPGDSJAK3IRAK4 | |
| SCHEMBL3534327 | 0.81 | JAK2 (0.70) | JAK2JAK1HPGDSJAK3IRAK4 | |
| SCHEMBL3542175 | 0.80 | JAK1 (0.68) | JAK2JAK1HPGDSJAK3IRAK4 | |
| SCHEMBL3542480 | 0.80 | JAK1 (0.68) | JAK2JAK1HPGDSJAK3IRAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6890929-B2 | Immunosuppressants; lupus, multiple sclerosis, skin disorders, antiarthritic agents, antihistamines, antiulcer agents, Crohn's disease | PFIZER, INC. (US) | 2005-05-10 | — | — | US | disclosed |
| EP-1087970-B1 | PYRROLO 2,3-d]PYRIMIDINE COMPOUNDS | PFIZER PROD INC (US) | 2004-04-28 | — | — | EP | disclosed |
| US-20030212273-A1 | Pyrrolo [2,3-D] pyrimidine compounds | PFIZER INC. | 2003-11-13 | — | — | US | disclosed |
| US-6610847-B2 | Tyrosine kinase inhibitors; immunosuppressants | PFIZER INC. | 2003-08-26 | — | — | US | disclosed |
| US-20020019526-A1 | Pyrrolo[2,3-d]pyrimidine compounds | PFIZER INC. | 2002-02-14 | — | — | US | disclosed |
| EP-1087970-A1 | PYRROLO 2,3-d]PYRIMIDINE COMPOUNDS | Pfizer Products Inc. (US) | 2001-04-04 | — | — | EP | disclosed |
| WO-1999065908-A1 | PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS | PFIZER PRODUCTS INC. (US) | 1999-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020019526-A1 | Pyrrolo[2,3-d]pyrimidine compounds | JAK1, JAK3, JAK2 | JAK2 3/4885JAK1 1/4885HPGDS 785/4885 |
| US-20030212273-A1 | Pyrrolo [2,3-D] pyrimidine compounds | JAK1, JAK3, JAK2 | JAK2 3/4885JAK1 1/4885HPGDS 785/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.